# Single Oral Dose of Bevenopran in Patients With Varying Degrees of Renal Impairment

> **NCT02508740** · PHASE1 · TERMINATED · sponsor: **Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 31 (actual)

## Conditions studied

- Renal Impairment

## Interventions

- **DRUG:** bevenopran

## Key facts

- **NCT ID:** NCT02508740
- **Lead sponsor:** Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-09
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** Development of compound has been put on hold.
- **Last updated:** 2015-07-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02508740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02508740, "Single Oral Dose of Bevenopran in Patients With Varying Degrees of Renal Impairment". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT02508740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*